» Articles » PMID: 34401312

Mitomycin Induced Pulmonary Veno-occlusive Disease

Overview
Date 2021 Aug 17
PMID 34401312
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary veno-occlusive disease (PVOD) is a rare but devastating cause of pulmonary hypertension (PH) characterized by preferential remodeling of the pulmonary venules. Mitomycin-C (MMC) is an alkylating agent commonly used in chemotherapy with documented lung toxicity as well as PVOD adverse effect. The incidence of PVOD in patients with anal cancer is much higher than in those with idiopathic PVOD, especially following treatment with MMC. An accurate diagnosis of PVOD can be made based on noninvasive investigations utilizing oxygen parameters, low diffusing capacity for carbon monoxide and characteristic signs on high-resolution computed tomography of the chest. No evidence-based medical therapy exists for PVOD at present and lung transplant remains the preferred definitive therapy for eligible patients. We present a case of autopsy confirmed MMC induced PVOD in a patient with metastatic anal cancer.

Citing Articles

Definition, classification and diagnosis of pulmonary hypertension.

Kovacs G, Bartolome S, Denton C, Gatzoulis M, Gu S, Khanna D Eur Respir J. 2024; 64(4).

PMID: 39209475 PMC: 11533989. DOI: 10.1183/13993003.01324-2024.


Treatment of stage I-III squamous cell anal cancer: a comparative effectiveness systematic review.

Troester A, Parikh R, Southwell B, Ester E, Sultan S, Greeno E J Natl Cancer Inst. 2024; 117(2):240-252.

PMID: 39163501 PMC: 11807441. DOI: 10.1093/jnci/djae195.


Inhalation of hydrogen gas protects against mitomycin-induced pulmonary veno-occlusive disease.

Zhang C, Xing Y, Wu X, Jiang Q, Luo X, He W Respir Res. 2024; 25(1):281.

PMID: 39014440 PMC: 11253336. DOI: 10.1186/s12931-024-02906-y.


Cancer Therapy-Related Pulmonary Hypertension: A Review of Mechanisms and Implications for Clinical Practice.

Gurdogan M, Demir M, Yalta K, Gulertop Y Anatol J Cardiol. 2023; 27(6):299-307.

PMID: 37257013 PMC: 10250770. DOI: 10.14744/AnatolJCardiol.2023.3013.

References
1.
Certain M, Chaumais M, Jais X, Savale L, Seferian A, Parent F . Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C. Chest. 2020; 159(3):1197-1207. DOI: 10.1016/j.chest.2020.09.238. View

2.
Botros L, van Nieuw Amerongen G, Vonk Noordegraaf A, Bogaard H . Recovery from mitomycin-induced pulmonary arterial hypertension. Ann Am Thorac Soc. 2014; 11(3):468-70. DOI: 10.1513/AnnalsATS.201312-426LE. View

3.
Resten A, Maitre S, Humbert M, Rabiller A, Sitbon O, Capron F . Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol. 2004; 183(1):65-70. DOI: 10.2214/ajr.183.1.1830065. View

4.
Ogawa A, Takahashi Y, Matsubara H . Clinical prediction score for identifying patients with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis. J Cardiol. 2018; 72(3):255-260. DOI: 10.1016/j.jjcc.2018.02.009. View

5.
Montani D, Lau E, Dorfmuller P, Girerd B, Jais X, Savale L . Pulmonary veno-occlusive disease. Eur Respir J. 2016; 47(5):1518-34. DOI: 10.1183/13993003.00026-2016. View